BRIEF-ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75

Reuters

2025/11/07

Nov 07 (Reuters) - ANI Pharmaceuticals Q3 EPS USD 1.13.

Q3 net income USD 26.3 million
Q3 revenue USD 227.8 million vs. IBES estimate USD 211 million
Q3 adjusted EBITDA USD 59.6 million
outlook FY revenue USD 854-873 million
outlook FY adjusted EBITDA USD 221-228 million
outlook FY adjusted EPS USD 7.37-7.64

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581002854"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581002854\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581002854?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581002854","market":"us","top_or_hot":-1,"title":"BRIEF-ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75</title>\n</head>\n<body>\n<p>Nov 07 (Reuters) - ANI Pharmaceuticals Q3 EPS USD 1.13.</p>\n<ul>\n<li>Q3 net income USD 26.3 million</li>\n<li>Q3 revenue USD 227.8 million vs. IBES estimate USD 211 million</li>\n<li>Q3 adjusted EBITDA USD 59.6 million</li>\n<li>outlook FY revenue USD 854-873 million</li>\n<li>outlook FY adjusted EBITDA USD 221-228 million</li>\n<li>outlook FY adjusted EPS USD 7.37-7.64</li>\n</ul>\n</body>\n</html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 19:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75</title>\n</head>\n<body>\n<p>Nov 07 (Reuters) - ANI Pharmaceuticals Q3 EPS USD 1.13.</p>\n<ul>\n<li>Q3 net income USD 26.3 million</li>\n<li>Q3 revenue USD 227.8 million vs. IBES estimate USD 211 million</li>\n<li>Q3 adjusted EBITDA USD 59.6 million</li>\n<li>outlook FY revenue USD 854-873 million</li>\n<li>outlook FY adjusted EBITDA USD 221-228 million</li>\n<li>outlook FY adjusted EPS USD 7.37-7.64</li>\n</ul>\n</body>\n</html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLX7CE689:1","article_id":"2581002854","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581002854","pubTimestamp":1762516246,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nov 07  - ANI Pharmaceuticals Q3 EPS USD 1.13.Q3 revenue USD 227.8 million vs. IBES estimate USD 211 million","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU0566484027.USD":"安本美国小盘成长股","ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"简介-ANI Pharmaceuticals第三季度调整后每股收益为2.04美元，而IBES预估为1.75美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":0.9},"content_text":"BRIEF-ANI Pharmaceuticals Q3 Adjusted EPS USD 2.04 Vs. IBES Estimate USD 1.75\n\n\nNov 07 (Reuters) - ANI Pharmaceuticals Q3 EPS USD 1.13.\n\nQ3 net income USD 26.3 million\nQ3 revenue USD 227.8 million vs. IBES estimate USD 211 million\nQ3 adjusted EBITDA USD 59.6 million\noutlook FY revenue USD 854-873 million\noutlook FY adjusted EBITDA USD 221-228 million\noutlook FY adjusted EPS USD 7.37-7.64","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}